206 related articles for article (PubMed ID: 23079614)
1. [Invasive fungal infection in haematology patients].
Vallejo Llamas JC; Ruiz-Camps I
Enferm Infecc Microbiol Clin; 2012 Nov; 30(9):572-9. PubMed ID: 23079614
[TBL] [Abstract][Full Text] [Related]
2. [Invasive mould disease in haematological patients].
Ruiz-Camps I; Jarque I
Rev Iberoam Micol; 2014; 31(4):249-54. PubMed ID: 25434346
[TBL] [Abstract][Full Text] [Related]
3. Changing strategies for the management of invasive fungal infections.
Rapp RP
Pharmacotherapy; 2004 Feb; 24(2 Pt 2):4S-28S; quiz 29S-32S. PubMed ID: 14992487
[TBL] [Abstract][Full Text] [Related]
4. Antifungal treatment strategies in high risk patients.
Rüping MJ; Vehreschild JJ; Cornely OA
Mycoses; 2008 Sep; 51 Suppl 2():46-51. PubMed ID: 18721331
[TBL] [Abstract][Full Text] [Related]
5. Current therapeutic approaches to fungal infections in immunocompromised hematological patients.
Pagano L; Caira M; Valentini CG; Posteraro B; Fianchi L
Blood Rev; 2010 Mar; 24(2):51-61. PubMed ID: 20056300
[TBL] [Abstract][Full Text] [Related]
6. [Therapy of invasive mycoses in neutropenic patients with hematologic system diseases].
Glasmacher A; Just-Nübling G; Molitor E
Dtsch Med Wochenschr; 1998 Feb; 123(7):191-4. PubMed ID: 9505945
[No Abstract] [Full Text] [Related]
7. Invasive fungal infections: epidemiology and analysis of antifungal prescriptions in onco-haematology.
des Champs-Bro B; Leroy-Cotteau A; Mazingue F; Pasquier F; François N; Corm S; Lemaitre L; Poulain D; Yakoub-Agha I; Alfandari S; Sendid B
J Clin Pharm Ther; 2011 Apr; 36(2):152-60. PubMed ID: 21366643
[TBL] [Abstract][Full Text] [Related]
8. Evaluating prophylaxis of invasive fungal infections in patients with haematologic malignancies.
Maertens J
Eur J Haematol; 2007 Apr; 78(4):275-82. PubMed ID: 17241370
[TBL] [Abstract][Full Text] [Related]
9. Recommendations for the treatment of invasive fungal infection caused by filamentous fungi in the hematological patient.
Barberán J; Mensa J; Llamas JC; Ramos IJ; Ruiz JC; Marín JR; Tello PB; Massana MB; Vidal JB; Viñas JM; Huelva FJ; Pons EC; Mediavilla JD; Morfa ML; Barrigón FE; Avellán PF; López SG; García CG; Maraver DH; Guía AL; Jiménez JL; Chacón EM; Rubio MO; Oteyza JP; Ramírez GR; Contreras RR; Barbero AR; Tarrats MR; Félix DR; Godoy PS; Salinas AS; Alonso MA; Torroba Jde L; Ferreiras DV; López LV; García JM; Perea JR; Moreno RC; Cáncer RC; Abete JF; Rodríguez JG; Gómez JG; Pedrosa EG; Baranda JM; García FJ; Camps IR; Lleti MS; Cisneros Jde L;
Rev Esp Quimioter; 2011 Dec; 24(4):263-70. PubMed ID: 22173196
[TBL] [Abstract][Full Text] [Related]
10. Strategies for managing systemic fungal infection and the place of itraconazole.
Potter M
J Antimicrob Chemother; 2005 Sep; 56 Suppl 1():i49-i54. PubMed ID: 16120634
[TBL] [Abstract][Full Text] [Related]
11. Systematic review and mixed treatment comparison meta-analysis of randomized clinical trials of primary oral antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients.
Bow EJ; Vanness DJ; Slavin M; Cordonnier C; Cornely OA; Marks DI; Pagliuca A; Solano C; Cragin L; Shaul AJ; Sorensen S; Chambers R; Kantecki M; Weinstein D; Schlamm H
BMC Infect Dis; 2015 Mar; 15():128. PubMed ID: 25887385
[TBL] [Abstract][Full Text] [Related]
12. Patients at high risk of invasive fungal infections: when and how to treat.
Rüping MJ; Vehreschild JJ; Cornely OA
Drugs; 2008; 68(14):1941-62. PubMed ID: 18778118
[TBL] [Abstract][Full Text] [Related]
13. The place for itraconazole in treatment.
Maertens J; Boogaerts M
J Antimicrob Chemother; 2005 Sep; 56 Suppl 1():i33-i38. PubMed ID: 16120632
[TBL] [Abstract][Full Text] [Related]
14. Posaconazole: an extended-spectrum triazole antifungal agent.
Schiller DS; Fung HB
Clin Ther; 2007 Sep; 29(9):1862-86. PubMed ID: 18035188
[TBL] [Abstract][Full Text] [Related]
15. New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance.
Fera MT; La Camera E; De Sarro A
Expert Rev Anti Infect Ther; 2009 Oct; 7(8):981-98. PubMed ID: 19803707
[TBL] [Abstract][Full Text] [Related]
16. Evaluating the role of prophylaxis in the management of invasive fungal infections in patients with hematologic malignancy.
Cornely OA; Aversa F; Cook P; Jones B; Michallet M; Shea T; Vallejo C
Eur J Haematol; 2011 Oct; 87(4):289-301. PubMed ID: 21752098
[TBL] [Abstract][Full Text] [Related]
17. Antifungal prophylaxis and therapy in patients with hematological malignancies and hematopoietic stem cell transplant recipients.
Almyroudis NG; Segal BH
Expert Rev Anti Infect Ther; 2010 Dec; 8(12):1451-66. PubMed ID: 21133669
[TBL] [Abstract][Full Text] [Related]
18. Treatment of invasive fungal infections in cancer patients--recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).
; Böhme A; Ruhnke M; Buchheidt D; Cornely OA; Einsele H; Enzensberger R; Hebart H; Heinz W; Junghanss C; Karthaus M; Krüger W; Krug U; Kubin T; Penack O; Reichert D; Reuter S; Silling G; Südhoff T; Ullmann AJ; Maschmeyer G
Ann Hematol; 2009 Feb; 88(2):97-110. PubMed ID: 18853161
[TBL] [Abstract][Full Text] [Related]
19. Antifungal prophylaxis for invasive mycoses in high risk patients.
Ullmann AJ; Cornely OA
Curr Opin Infect Dis; 2006 Dec; 19(6):571-6. PubMed ID: 17075333
[TBL] [Abstract][Full Text] [Related]
20. Antifungal prophylaxis among allogeneic hematopoietic stem cell transplant recipients: current issues and new agents.
Strasfeld L; Weinstock DM
Expert Rev Anti Infect Ther; 2006 Jun; 4(3):457-68. PubMed ID: 16771622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
